NASDAQ:VICL - Vical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.23 +0.02 (+1.65 %) (As of 03/22/2019 04:00 PM ET)Previous Close$1.21Today's Range$1.21 - $1.2552-Week Range$0.85 - $1.82Volume221,400 shsAverage Volume383,934 shsMarket Capitalization$26.84 millionP/E Ratio-1.52Dividend YieldN/ABeta0.53 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company is developing VCL-HB01, an HSV-2 therapeutic vaccine that is in Phase II clinical trial to prevent and protect against lesion recurrence, as well as for the treatment of patients with symptomatic genital herpes infection; VL-2397 antifungal program, which is in Phase II clinical trial for the treatment of invasive fungal infections; and chronic hepatitis B that is in preclinical stage for the eradication of persistent HBV infection. Vical Incorporated has a license agreement with Astellas Pharma Inc. to develop and commercialize VL-2397 antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California. Receive VICL News and Ratings via Email Sign-up to receive the latest news and ratings for VICL and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:VICL Previous Symbol CUSIP92560210 CIK819050 Webwww.vical.com Phone858-646-1100Debt Debt-to-Equity RatioN/A Current Ratio13.74 Quick Ratio13.74Price-To-Earnings Trailing P/E Ratio-1.52 Forward P/E Ratio-2.56 P/E GrowthN/A Sales & Book Value Annual Sales$1.62 million Price / Sales16.57 Cash FlowN/A Price / Cash FlowN/A Book Value$2.24 per share Price / Book0.55Profitability EPS (Most Recent Fiscal Year)($0.81) Net Income$-16,250,000.00 Net Margins-1,002.10% Return on Equity-33.58% Return on Assets-31.59%Miscellaneous EmployeesN/A Outstanding Shares21,820,000Market Cap$26.84 million Next Earnings Date5/2/2019 (Estimated) OptionableOptionable Vical (NASDAQ:VICL) Frequently Asked Questions What is Vical's stock symbol? Vical trades on the NASDAQ under the ticker symbol "VICL." How were Vical's earnings last quarter? Vical Incorporated (NASDAQ:VICL) released its earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.17) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.17). The biotechnology company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.04 million. Vical had a negative net margin of 1,002.10% and a negative return on equity of 33.58%. View Vical's Earnings History. When is Vical's next earnings date? Vical is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Vical. What price target have analysts set for VICL? 2 analysts have issued 1 year price objectives for Vical's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Vical's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 225.2% from the stock's current price. View Analyst Price Targets for Vical. What is the consensus analysts' recommendation for Vical? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vical in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vical. Has Vical been receiving favorable news coverage? News articles about VICL stock have trended somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vical earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the stock's share price in the next several days. Who are some of Vical's key competitors? Some companies that are related to Vical include Nantkwest (NK), Aptose Biosciences (APTO), Brainstorm Cell Therapeutics (BCLI), Outlook Therapeutics (OTLK), Genocea Biosciences (GNCA), Applied Genetic Technologies (AGTC), Idera Pharmaceuticals (IDRA), INmune Bio (INMB), Cidara Therapeutics (CDTX), Proteon Therapeutics (PRTO), BioCardia (BCDA), Oncobiologics (ONS), Pharmacyte Biotech (PMCB), Entera Bio (ENTX) and Curis (CRIS). What other stocks do shareholders of Vical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vical investors own include Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Cytori Therapeutics (CYTX), Trevena (TRVN), CTI BioPharma (CTIC), Curis (CRIS), Catalyst Pharmaceuticals (CPRX), Eyepoint Pharmaceuticals (EYPT), Genocea Biosciences (GNCA) and Agenus (AGEN). Who are Vical's key executives? Vical's management team includes the folowing people: Mr. Vijay B. Samant, CEO, Pres & Director (Age 66)Mr. Anthony Alan Ramos, VP, CFO & Chief Accounting Officer (Age 52)Dr. Lawrence Russell Smith, Sr. VP of Research (Age 58)Dr. Mammen P. Mammen Jr., Sr. VP of Clinical Devel. (Age 55) Who are Vical's major shareholders? Vical's stock is owned by a number of of institutional and retail investors. Top institutional investors include Two Sigma Investments LP (0.14%). Company insiders that own Vical stock include Anthony Alan Ramos, Armistice Capital Master Fund, Armistice Capital, Llc and Robert C Merton. View Institutional Ownership Trends for Vical. Which institutional investors are selling Vical stock? VICL stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP. View Insider Buying and Selling for Vical. How do I buy shares of Vical? Shares of VICL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Vical's stock price today? One share of VICL stock can currently be purchased for approximately $1.23. How big of a company is Vical? Vical has a market capitalization of $26.84 million and generates $1.62 million in revenue each year. The biotechnology company earns $-16,250,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. What is Vical's official website? The official website for Vical is http://www.vical.com. How can I contact Vical? Vical's mailing address is 10390 PACIFIC CENTER COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-646-1100 or via email at www.vical.com. MarketBeat Community Rating for Vical (NASDAQ VICL)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 223 (Vote Outperform)Underperform Votes: 157 (Vote Underperform)Total Votes: 380MarketBeat's community ratings are surveys of what our community members think about Vical and other stocks. Vote "Outperform" if you believe VICL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VICL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/23/2019 by MarketBeat.com StaffFeatured Article: Why are analyst ratings important in trading stocks?